MONOCLONAL ANTIBODY THERAPY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-05-25 | Pages: 200+ | Report ID: BYR-182242 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Monoclonal Antibody Therapy Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET
7.1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Abbvie Inc
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Merck & Co.,Inc
16.3 F.Hoffman-La Roche Ltd
16.4 Bristol Mayor Squibb Company
16.5 Johnson & Johnson
16.6 Daiichi Sankyo Company,Ltd
16.7 Novartis AG
16.8 Alexion Pharmaceuticals, Inc
16.9 Amgen
16.10 Bayer AG
16.11 Biogen Inc
16.12 GenScript
16.13 GlaxoSmithKline Plc
16.14 Pfizer Inc.
16.15 Sanofi
16.16 Sigma-Aldrich Co. LLC
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeHuman Monoclonal Antibody
Humanized Monoclonal Antibody
Chimeric Monoclonal Antibody
Murine  Monoclonal Antibody
By Application
Cancer
Autoimmune Diseases
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Companies
Abbvie Inc
Merck & Co.,Inc
F.Hoffman-La Roche Ltd
Bristol Mayor Squibb Company
Johnson & Johnson
Daiichi Sankyo Company,Ltd
Novartis AG
Alexion Pharmaceuticals, Inc
Amgen
Bayer AG
Biogen Inc
GenScript
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi
Sigma-Aldrich Co. LLC
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.